Fig. 1 · Structure

Documents & Downloads

Puerarin (Kakonein)

Cat. No. A10759 CAS 3681-99-0

5-HT2C receptor antagonist

Puerarin is one of several known isoflavones. Puerarin is a 5-HT2C receptor and benzodiazepine site antagonist. Puerarin is being investigated as a self-microemulsifying drug delivery system.

In Stock

Publications for Puerarin

3 publications citing this product

  1. Takashi Azuma, .et al. , SEP PURIF TECHNOL, 2019, Apr; 212: 483-489
  2. Azuma T, .et al. , Environ Sci Pollut Res Int, 2017, Aug;24(23):19021-19030 PMID: 28660504
  3. Azuma T, .et al. , Sci Total Environ, 2016, Apr 1;548-549:189-197 PMID: 26802347

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In high-glucose-exposed murine podocytes, puerarin reduced NOX4 mRNA expression. This supports cellular regulation of NOX4 expression; the experiment does not establish direct enzyme inhibition or target binding. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
5-HT2C Receptor  

Puerarin (Kakonein) Research Summary

This section summarizes 1 in vitro study and 1 in vivo study of Puerarin (Kakonein) from 2 published references.

Puerarin (Kakonein) In Vitro Studies

Puerarin (10 μM) reduced DCF-positive cells after 24 h and NOX4 transcripts after 4 h in murine podocytes exposed to 30 mM glucose, compared with high-glucose vehicle controls. DCF fluorescence provides a cellular oxidative-stress readout. [1]

Puerarin effects on oxidative fluorescence and NOX4 transcripts in podocytes

Cell-based study · Conditionally immortalized, differentiated murine podocytes under high glucose (30 mM), with normal-glucose/mannitol and DMSO controls. [1]

At 10 μM, puerarin reduced the high-glucose-associated DCF-positive cell fraction and NOX4 mRNA relative to high-glucose vehicle controls. The experiment measures cellular fluorescence and gene expression. It does not establish direct NOX4 binding, enzyme inhibition, or a biochemical IC50.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Fraction of DCF-positive cells among DAPI-positive cells under high glucoseDirectional fluorescence response Reduced versus high-glucose vehicle; ***P < 0.001; n = 3, 7 fields per group (Figure 4B caption).[1]
NOX4 transcript expression normalized to GAPDHRelative mRNA expression Reduced versus high-glucose vehicle; Figure 4C marks **P < 0.01 for this contrast; n = 3. No exact fold value extracted.[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
24 h for DCF fluorescence; 4 h for NOX4 mRNA
Method
Addition to cultured podocytes under normal- or high-glucose conditions.
Vehicle
DMSO vehicle; ROS methods specify 5% DMSO. Final vehicle concentration for the PCR assay is not separately specified.
Co-treatment
High glucose (30 mM) is the injury condition; no second pharmacological treatment in adopted Figure 4A–C.
Reported limits
Normal-glucose control is 5 mM glucose + 25 mM mannitol in Figure 4 caption, versus 5.5 mM + 24.5 mM in ROS methods. Exact normal-control composition remains inconsistent. The HG-versus-HG vehicle comparison is unambiguous. n = 3 is reported without explicit donor/biological-unit definition.
Methods and source locations

Compound reported in the paper: Puerarin; Compound label in the paper: Sigma-Aldrich puerarin; unmodified compound as named by authors

Cellular effects of named puerarin in murine podocytes; no Adooq-specific activity or direct-enzyme potency claim.

Figure 4A–C and caption; Methods: Reactive oxygen species measurement, Real time PCR, Cell culture, Statistical analysis

Fraction of DCF-positive cells among DAPI-positive cells under high glucose: DCFDA staining after 24 h treatment; image-based DCF+/DAPI+ cell ratio. DCF fluorescence is not a species-specific superoxide measurement. — Figure 4A,B and caption; Methods: Reactive oxygen species measurement

NOX4 transcript expression normalized to GAPDH: Real-time PCR after 4 h treatment; GAPDH internal control. — Figure 4C image and caption; Methods: Real time PCR

Puerarin (Kakonein) In Vivo Studies

In male rats undergoing rapid maxillary expansion, local puerarin (15 mg/kg/day) increased mid-palatal bone volume relative to expansion vehicle at day 14. Bone volume remained below untreated controls, and expansion width did not significantly differ between the two expansion groups. [2]

Local puerarin during rapid maxillary expansion in rats

Animal study · Male Wistar rats, 6 weeks old; rapid maxillary expansion model with untreated and expansion-vehicle controls. [2]

Local puerarin during a 14-day expansion experiment increased mid-palatal bone volume relative to expansion vehicle. Bone volume remained below untreated controls. Expansion width and body weight did not significantly differ between the two expansion groups. Both expansion groups initially lost weight.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mid-palatal bone volume in a fixed 2.0 mm × 1.0 mm × 0.8 mm region of interest at day 14Micro-CT bone volume Puerarin group > expansion-vehicle group, P < 0.01; puerarin group < untreated control, P < 0.01; n = 6 per group; mean ± SD. No exact volume inferred from bars.[2]
Mid-palatal suture width at day 14Micro-CT suture width No significant difference between puerarin and expansion-vehicle groups (P > 0.05); both expanded versus untreated controls; n = 6 per group; mean ± SD.[2]
Body weight over the 14-day expansion experimentBody-weight course No significant difference between the two expansion groups (P > 0.05). Both expansion groups lost weight during days 1–5, unlike the untreated controls; n = 6 per group; mean ± SD.[2]

Conditions shared by the study groups

Route
Local injection into the space between the frontal periosteum and the maxillary suture.
Frequency
Daily dose as reported in mg/kg/day.
Treatment course
14-day expansion experiment; exact first and last injection day not separately stated.
Vehicle
Dissolved in 2% DMSO, then diluted with saline; final DMSO fraction after dilution not stated.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Maxillary expansion plus local puerarin
15 mg/kg/day
Expansion plus saline containing 2% DMSO (group 2), and untreated rats without expansion (group 1). The paper labels the saline control as 15 mg/kg/day; no saline mass dose is inferred.At day 14, bone volume was higher than expansion vehicle (P < 0.01) but lower than untreated controls (P < 0.01). Expansion width and body weight did not significantly differ between the two expansion groups (P > 0.05).[2]
Maxillary expansion plus local puerarin
Model: Six 6-week-old male Wistar rats undergoing rapid maxillary expansion; total experiment 18 rats in three randomized groups, six per group.
Reported limits: Injection volume and final vehicle fraction are not specified. Injection-day count is not separately enumerated. Local treatment with expansion does not establish systemic efficacy.
Methods and source locations

Compound reported in the paper: Puerarin; Compound label in the paper: GlpBio GN10680, as named in study materials

Reported local treatment in male rats undergoing expansion; no systemic, clinical relapse-prevention or Adooq-lot claim.

Figure 6A–C and caption; Materials and Methods: Animal Experimental Design and Appliance Placement, Micro-CT Scanning of the Hard Palate, Statistical Analysis; Results: Changes in Body Weight and Mid-Palatal Suture Widths

Mid-palatal bone volume in a fixed 2.0 mm × 1.0 mm × 0.8 mm region of interest at day 14: Micro-CT and reconstructed fixed-region bone-volume analysis; one-way ANOVA. — Figure 6C and caption; Results: Changes in Body Weight and Mid-Palatal Suture Widths; Methods: Micro-CT Scanning of the Hard Palate

Mid-palatal suture width at day 14: Micro-CT width at the mid-coronal plane of the upper first molar; one-way ANOVA. — Figure 6B and caption; Results: Changes in Body Weight and Mid-Palatal Suture Widths

Body weight over the 14-day expansion experiment: Daily weight monitoring; Figure 6A analyzed by two-way ANOVA. — Figure 6A and caption; Results: Changes in Body Weight and Mid-Palatal Suture Widths

Maxillary expansion plus local puerarin · Figure 6A–C and caption; Materials and Methods: Animal Experimental Design and Appliance Placement, Micro-CT Scanning of the Hard Palate, Statistical Analysis; Results: Changes in Body Weight and Mid-Palatal Suture Widths

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 3681-99-0
Applications 5-HT2C receptor antagonist
Formula C21H20O9
Molecular Weight 416.4
Synonyms NPI-31G; Kakonein
SMILES
C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 80 mg/mL (192.13 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Puerarin (Kakonein) Research References

  1. [1] Xueling Li, Weijing Cai, Kyung Lee, et al. Puerarin attenuates diabetic kidney injury through the suppression of NOX4 expression in podocytes Scientific Reports (2017). PMID: 29097815 DOI: 10.1038/s41598-017-14906-8 Source material
  2. [2] Yanran Yang, Daiyun Chen, Yilin Li, et al. Effect of Puerarin on Osteogenic Differentiation in vitro and on New Bone Formation in vivo Drug Design, Development and Therapy (2022). PMID: 36060929 DOI: 10.2147/DDDT.S379794 Source material

Publications

3 publications citing this product

  1. Takashi Azuma, .et al. , SEP PURIF TECHNOL, 2019, Apr; 212: 483-489
  2. Azuma T, .et al. , Environ Sci Pollut Res Int, 2017, Aug;24(23):19021-19030 PMID: 28660504
  3. Azuma T, .et al. , Sci Total Environ, 2016, Apr 1;548-549:189-197 PMID: 26802347

Added to your cart

View Cart Checkout
Loading...